Investor Relations

Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Investor Contact Information


Emmaus Life Sciences, Inc.
21250 Hawthorne Blvd.
Suite 800
Torrance, CA 90503
T: 310-214-0065

Transfer Agent

American Stock Transfer & Trust Company
Brooklyn, NY
T: 800-937-5449 / 718-921-8124

Some of the statements contained on this website, which are not historical facts, are forward-looking statements, which by their nature involve risks and uncertainties.  For further information on factors that could affect Emmaus Life Sciences, please refer to the company‚Äôs periodic filings with the Securities and Exchange Commission.

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.